244 related articles for article (PubMed ID: 28356599)
1. Towards Personalized Medicine in Melanoma: Implementation of a Clinical Next-Generation Sequencing Panel.
de Unamuno Bustos B; Murria Estal R; Pérez Simó G; de Juan Jimenez I; Escutia Muñoz B; Rodríguez Serna M; Alegre de Miquel V; Llavador Ros M; Ballester Sánchez R; Nagore Enguídanos E; Palanca Suela S; Botella Estrada R
Sci Rep; 2017 Mar; 7(1):495. PubMed ID: 28356599
[TBL] [Abstract][Full Text] [Related]
2. Quality assessment of a clinical next-generation sequencing melanoma panel within the Italian Melanoma Intergroup (IMI).
Vanni I; Casula M; Pastorino L; Manca A; Dalmasso B; Andreotti V; Pisano M; Colombino M; ; Pfeffer U; Tanda ET; Rozzo C; Paliogiannis P; Cossu A; Ghiorzo P; Palmieri G;
Diagn Pathol; 2020 Dec; 15(1):143. PubMed ID: 33317587
[TBL] [Abstract][Full Text] [Related]
3. Implementation of next generation sequencing technology for somatic mutation detection in routine laboratory practice.
Giardina T; Robinson C; Grieu-Iacopetta F; Millward M; Iacopetta B; Spagnolo D; Amanuel B
Pathology; 2018 Jun; 50(4):389-401. PubMed ID: 29752127
[TBL] [Abstract][Full Text] [Related]
4. Mutation Yield of a 34-Gene Solid Tumor Panel in Community-Based Tumor Samples.
Sanders H; Qu K; Li H; Ma L; Barlan C; Zhang X; Prentice J; Wolfson D; Crossley B; Sferruzza A; Sninsky J; Ross D; Grupe A; Catanese J; Hantash F; Waldman F
Mol Diagn Ther; 2016 Jun; 20(3):241-53. PubMed ID: 27084556
[TBL] [Abstract][Full Text] [Related]
5. Clinical Validation and Implementation of a Targeted Next-Generation Sequencing Assay to Detect Somatic Variants in Non-Small Cell Lung, Melanoma, and Gastrointestinal Malignancies.
Fisher KE; Zhang L; Wang J; Smith GH; Newman S; Schneider TM; Pillai RN; Kudchadkar RR; Owonikoko TK; Ramalingam SS; Lawson DH; Delman KA; El-Rayes BF; Wilson MM; Sullivan HC; Morrison AS; Balci S; Adsay NV; Gal AA; Sica GL; Saxe DF; Mann KP; Hill CE; Khuri FR; Rossi MR
J Mol Diagn; 2016 Mar; 18(2):299-315. PubMed ID: 26801070
[TBL] [Abstract][Full Text] [Related]
6. Development of a gene panel for next-generation sequencing of clinically relevant mutations in cell-free DNA from cancer patients.
Malapelle U; Mayo de-Las-Casas C; Rocco D; Garzon M; Pisapia P; Jordana-Ariza N; Russo M; Sgariglia R; De Luca C; Pepe F; Martinez-Bueno A; Morales-Espinosa D; González-Cao M; Karachaliou N; Viteri Ramirez S; Bellevicine C; Molina-Vila MA; Rosell R; Troncone G
Br J Cancer; 2017 Mar; 116(6):802-810. PubMed ID: 28170370
[TBL] [Abstract][Full Text] [Related]
7. Clinical evaluation of panel testing by next-generation sequencing (NGS) for gene mutations in myeloid neoplasms.
Au CH; Wa A; Ho DN; Chan TL; Ma ES
Diagn Pathol; 2016 Jan; 11():11. PubMed ID: 26796102
[TBL] [Abstract][Full Text] [Related]
8. Clinical applicability and cost of a 46-gene panel for genomic analysis of solid tumours: Retrospective validation and prospective audit in the UK National Health Service.
Hamblin A; Wordsworth S; Fermont JM; Page S; Kaur K; Camps C; Kaisaki P; Gupta A; Talbot D; Middleton M; Henderson S; Cutts A; Vavoulis DV; Housby N; Tomlinson I; Taylor JC; Schuh A
PLoS Med; 2017 Feb; 14(2):e1002230. PubMed ID: 28196074
[TBL] [Abstract][Full Text] [Related]
9. Assessing the Diagnostic Yield of Targeted Next-Generation Sequencing for Melanoma and Gastrointestinal Tumors.
Garg S; Grenier S; Misyura M; Sukhai MA; Thomas M; Kamel-Reid S; Stockley T
J Mol Diagn; 2020 Apr; 22(4):467-475. PubMed ID: 32036084
[TBL] [Abstract][Full Text] [Related]
10. Cost Effectiveness of Sequencing 34 Cancer-Associated Genes as an Aid for Treatment Selection in Patients with Metastatic Melanoma.
Li Y; Bare LA; Bender RA; Sninsky JJ; Wilson LS; Devlin JJ; Waldman FM
Mol Diagn Ther; 2015 Jun; 19(3):169-77. PubMed ID: 25926090
[TBL] [Abstract][Full Text] [Related]
11. Next-Generation Sequencing Reveals Pathway Activations and New Routes to Targeted Therapies in Cutaneous Metastatic Melanoma.
Carlson JA; Caldeira Xavier JC; Tarasen A; Sheehan CE; Otto G; Miller VA; Stephens PJ; Elvin JA; Vergilio JA; Suh J; Gay LM; Ross JS
Am J Dermatopathol; 2017 Jan; 39(1):1-13. PubMed ID: 28045747
[TBL] [Abstract][Full Text] [Related]
12. Performance validation of an amplicon-based targeted next-generation sequencing assay and mutation profiling of 648 Chinese colorectal cancer patients.
Wang Y; Liu H; Hou Y; Zhou X; Liang L; Zhang Z; Shi H; Xu S; Hu P; Zheng Z; Liu R; Tang T; Ye F; Liang Z; Bu H
Virchows Arch; 2018 Jun; 472(6):959-968. PubMed ID: 29705968
[TBL] [Abstract][Full Text] [Related]
13. Somatic mutation analysis in melanoma using targeted next generation sequencing.
Miraflor AP; de Abreu FB; Peterson JD; Turner SA; Amos CI; Tsongalis GJ; Yan S
Exp Mol Pathol; 2017 Oct; 103(2):172-177. PubMed ID: 28822769
[TBL] [Abstract][Full Text] [Related]
14. Anchored Multiplex PCR Custom Melanoma Next Generation Sequencing Panel for Analysis of Circulating Tumor DNA.
Diefenbach RJ; Lee JH; Stewart A; Menzies AM; Carlino MS; Saw RPM; Stretch JR; Long GV; Scolyer RA; Rizos H
Front Oncol; 2022; 12():820510. PubMed ID: 35494035
[TBL] [Abstract][Full Text] [Related]
15. Targeted next generation sequencing of mucosal melanomas identifies frequent NF1 and RAS mutations.
Cosgarea I; Ugurel S; Sucker A; Livingstone E; Zimmer L; Ziemer M; Utikal J; Mohr P; Pfeiffer C; Pföhler C; Hillen U; Horn S; Schadendorf D; Griewank KG; Roesch A
Oncotarget; 2017 Jun; 8(25):40683-40692. PubMed ID: 28380455
[TBL] [Abstract][Full Text] [Related]
16. Association Between NRAS and BRAF Mutational Status and Melanoma-Specific Survival Among Patients With Higher-Risk Primary Melanoma.
Thomas NE; Edmiston SN; Alexander A; Groben PA; Parrish E; Kricker A; Armstrong BK; Anton-Culver H; Gruber SB; From L; Busam KJ; Hao H; Orlow I; Kanetsky PA; Luo L; Reiner AS; Paine S; Frank JS; Bramson JI; Marrett LD; Gallagher RP; Zanetti R; Rosso S; Dwyer T; Cust AE; Ollila DW; Begg CB; Berwick M; Conway K;
JAMA Oncol; 2015 Jun; 1(3):359-68. PubMed ID: 26146664
[TBL] [Abstract][Full Text] [Related]
17. A high-throughput panel for identifying clinically relevant mutation profiles in melanoma.
Dutton-Regester K; Irwin D; Hunt P; Aoude LG; Tembe V; Pupo GM; Lanagan C; Carter CD; O'Connor L; O'Rourke M; Scolyer RA; Mann GJ; Schmidt CW; Herington A; Hayward NK
Mol Cancer Ther; 2012 Apr; 11(4):888-97. PubMed ID: 22383533
[TBL] [Abstract][Full Text] [Related]
18. Validation of an NGS mutation detection panel for melanoma.
Reiman A; Kikuchi H; Scocchia D; Smith P; Tsang YW; Snead D; Cree IA
BMC Cancer; 2017 Feb; 17(1):150. PubMed ID: 28228113
[TBL] [Abstract][Full Text] [Related]
19. Clinical Targeted Next-Generation sequencing Panels for Detection of Somatic Variants in Gliomas.
Shin H; Sa JK; Bae JS; Koo H; Jin S; Cho HJ; Choi SW; Kyoung JM; Kim JY; Seo YJ; Joung JG; Kim NKD; Son DS; Chung J; Lee T; Kong DS; Choi JW; Seol HJ; Lee JI; Suh YL; Park WY; Nam DH
Cancer Res Treat; 2020 Jan; 52(1):41-50. PubMed ID: 31096737
[TBL] [Abstract][Full Text] [Related]
20. Dual NRASQ61R and BRAFV600E mutation-specific immunohistochemistry completes molecular screening in melanoma samples in a routine practice.
Uguen A; Guéguen P; Legoupil D; Bouvier S; Costa S; Duigou S; Lemasson G; Ledé F; Sassolas B; Talagas M; Férec C; Le Maréchal C; De Braekeleer M; Marcorelles P
Hum Pathol; 2015 Nov; 46(11):1582-91. PubMed ID: 26297254
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
